IMPLICATION OF PRIOR TREATMENT WITH DRUG-COMBINATIONS INCLUDING INHIBITORS OF TOPOISOMERASE-II IN THERAPY-RELATED MONOCYTIC LEUKEMIA WITH A 9-11 TRANSLOCATION
IMPLICATION OF PRIOR TREATMENT WITH DRUG-COMBINATIONS INCLUDING INHIBITORS OF TOPOISOMERASE-II IN THERAPY-RELATED MONOCYTIC LEUKEMIA WITH A 9-11 TRANSLOCATION
复制标题
DOI：
10.1002/gcc.2870020110
复制
发表时间：
1990-05-01
影响因子：
3.7
通讯作者：
SCHUMACHER, H
中科院分区：
文献类型：
--
作者：
ALBAIN, KS;LEBEAU, MM;SCHUMACHER, H
目前的情况下，连同其他报告在此审查，定义了一个新的亚型治疗相关的急性髓细胞白血病（t-AML）。这种t-AML变体的特征在于从初始药物治疗到骨髓功能障碍和单核细胞形态学的短间隔，而没有三系发育不良。与通常具有染色体5和/或7的异常的经典t-AML不同，这种新亚型的特征在于涉及染色体11的带q23的重排，最常见的是9;11易位。大多数t-AML患者既往接受过拓扑异构酶II反应性药物（包括蒽环类、表鬼白毒素或放线菌素D）联合烷化剂或顺铂的细胞毒性治疗。既往治疗（包括拓扑异构酶II反应性药物）与快速出现的涉及单核细胞系和染色体II的t-AML之间的关联需要进一步研究。
The present case, together with other reports reviewed herein, defines a new subtype of therapy-related acute myeloid leukemia (t-AML). This variant of t-AML is characterized by a short interval from initial drug therapy to bone marrow dysfunction and monocytic morphology without trilineage dysplasia. Unlike classic t-AML, which frequently has abnormalities of chromosomes 5 and/or 7, this new subtype is characterized by rearrangements involving band q23 of chromosome 11, most commonly a 9;11 translocation. The majority of patients with this subtype of t-AML had prior cytotoxic therapy with topoisomerase II-reactive drugs including anthracyclines, epipodophyllotoxins, or actinomycin D, combined with either an alkylating agent or cisplatin. This association of prior therapy which includes topoisomerase II-reactive agents and a rapidly appearing t-AML involving the monocytic line and chromosome II requires additional study.